From Combination Therapy Using Artificial Dermis and Basic Fibroblast Growth Factor to Artificial Dermis for Sustained Release of bFGF

Abstract

Since we developed an artificial dermis (Pelnac^®, Gunze, Ltd., Kyoto, Japan), we have created improvements based on problems encountered in clinical use.
During the period until secondary grafting, low resistance to infection is a clinical problem. To overcome this issue, topical application of basic fibroblast growth factor (bFGF) is beneficial to induce neovascularization and accelerate the regeneration of dermis-like granulation tissues in the artificial dermis. There fore, combination therapy using artificial dermis and bFGF has been established. However, since the in vivo half-life of bFGF is very short, repeated application into the artificial dermis is required in this combination therapy. We have developed a novel artificial dermis for sustained release of bFGF. In this paper, we report the deployment circumstances and the future role of this novel matrix.